地尔硫提高肝移植受者他克莫司血药浓度的临床研究  

Clinical research of Diltiazem on improving tacrolimus blood concentration after liver transplantation

作　　者：史政荣[1] 严律南[1] 李波[1] 文天夫[1] 曾勇[1] 赵纪春[1] 徐明清[1] 王文涛[1] 杨家印[1] 陈哲宇[1] 

机构地区：[1]四川大学华西医院,610041

出　　处：《山西医药杂志（上半月）》2009年第8期714-716,共3页Shanxi Medical Journal

摘　　要：目的评价地尔硫提高肝移植受者他克莫司血药浓度的疗效。方法选择116例肝移植术后长期口服他克莫司的受者,他克莫司和地尔硫同时口服的受者为试验组(58例),单纯口服他克莫司的受者为对照组(58例);检测两组全血他克莫司浓度,他克莫司用量及肝、肾功能,进行分析。结果试验组服药后他克莫司血药浓度比服药前增加了(4.5±0.5)μg/L,增幅达45.9%,用药前后比较差异有统计学意义(P<0.01);与对照组比较差异亦有统计学意义(P<0.01)。试验组他克莫司用量明显减少,肝、肾功能无明显不良影响,无明显不良反应。结论地尔硫能明显提高肝移植受者他克莫司血药浓度,未发现明显不良反应。Objective To evaluate the effect of diltiazem on improving tacrolimus blood concentration in liver transplantation patients. Methods One hundred and sixteen cases with long-term administration of FK506 after liver transplantation were research subjects. FK506 and diltiazem simultaneously administration were the test group （58 cases）, simple oral administration of FK506 for the control group （58 cases）. FK506 blood concentrations, FK506 dosage, liver and kidney function of the two groups were evaluated. Results After taking Dihiazem, FK506 blood concentrations of test group increased more （4.5±0.5）btg/L than pre-administration, representing an increase of 45.9%, that is more significant （P〈0.01）; compared with the control group there was significant difference too （P〈0.01）. Test group significantly reduced the dosage of FK506. There was no significant sideeffect about the hepatic function, renal function and other data. Conclusion Dihiazem can increase tacrolimus blood concentration after liver transplantation. No significant side effect was found.

关 键 词：地尔硫(艹卓) 肝移植 血药浓度 

分 类 号：R96[医药卫生—药理学]